Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Yarden

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Oncogene|February 28, 2024
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|April 11, 2025
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|December 20, 2011
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progressionF Pareja, D A Ferraro, C Rubin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Molecular and Cellular Biology|September 19, 1998
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor networkR Pinkas-Kramarski, M Shelly, B C Guarino, et al.
Cell Death & Disease|March 29, 2022
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transJ M Vicencio, R Evans, R Green, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Oncogene|February 28, 2024
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|April 11, 2025
Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC -R Pradeep, A Zeisel, W J Köstler, et al.
Oncogene|December 20, 2011
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progressionF Pareja, D A Ferraro, C Rubin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industryR Bartsch, S Frings, M Marty, et al.
Molecular and Cellular Biology|September 19, 1998
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor networkR Pinkas-Kramarski, M Shelly, B C Guarino, et al.
Cell Death & Disease|March 29, 2022
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transJ M Vicencio, R Evans, R Green, et al.
Pageof 17